A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

The scientists found that two medications significantly reduce the risk of developing dementia in life. A new study, ...

In the second study, a team led by Allie Seminer ... effects and that they are not guaranteed to prevent dementia." Newsweek has contacted Ozempic manufacturer Novo Nordisk for comment.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...